Small cell anaplastic carcinoma of the lung: Changing concepts and emerging problems

Authors

  • John C. Ruckdeschel M.D.,

    1. Assistant Professor of Medicine in Oncology, Albany Medical College, Albany, New York, Medical Director, Cancer Treatment Center, St. Mary's Hospital, Troy, New York, and American Cancer Society Junior Faculty Clinical Fellow
    Search for more papers by this author
  • Richard Caradonna M.D.,

    1. Formerly Oncology Fellow, Division of Oncology, Albany Medical College, Albany, New York, and Former American Cancer Society Fellow. Now in private practice of oncology in Albany, New York
    Search for more papers by this author
  • William J. Paladine M.D.,

    1. Formerly Head, Section of Medical Oncology, Albany Veterans Administration Hospital, Albany, New York, and American Cancer Society Fellow. Now in private practiceof oncology in Florida
    Search for more papers by this author
  • Stephen M. Hillinger M.D.,

    1. Assistant Professor of Medicine in Oncology, Albany Medical College, Albany, New York, and American Cancer Society Junior Faculty Clinical Fellow
    Search for more papers by this author
  • John Horton M.B., Ch.B

    1. Professor of Medicine and Head, Division of Oncology, Albany Medical College, Albany, New York
    Search for more papers by this author

Abstract

Small cell carcinoma of the lung has joined the ranks of cancers that are increasingly susceptible to successful therapeutic attack. Cautious optimism about potential cures is being expressed in a disease that a few short years ago had a median survival of two months. Advances in cell biology, particularly in the area of metastases, are leading to new concepts in therapy, but more than ever there is a crying need for controlled studies of new approaches.

Ancillary